Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study
- Written by PR Newswire
![]() |
A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes
MINNEAPOLIS, Jan. 31, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 Diabetes (T2D), announced that the U.S. Food and...
Read more: Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study















